The evolution of mendelian randomization for investigating drug effects.
MetadataShow full item record
Gill, D., & Burgess, S. (2022). The evolution of mendelian randomization for investigating drug effects.. PLoS medicine, 19 (2) https://doi.org/10.1371/journal.pmed.1003898
Dipender Gill and Stephen Burgess discuss the accompanying study by James Yarmolinsky and colleagues investigating the associations between genetically-proxied inhibition of antihypertensive drug targets and risk of common cancer subtypes using Mendelian randomization.
Humans, Colorectal Neoplasms, Antihypertensive Agents, Angiotensin-Converting Enzyme Inhibitors, Risk Factors, Blood Pressure, Genetic Variation, Genome-Wide Association Study, Mendelian Randomization Analysis
External DOI: https://doi.org/10.1371/journal.pmed.1003898
This record's URL: https://www.repository.cam.ac.uk/handle/1810/334718
Attribution 4.0 International
Licence URL: https://creativecommons.org/licenses/by/4.0/